Regeneron Pharmaceuticals, Inc. (REGN) Stock Analysis — Probabli.AI
AI-powered analysis for REGN (Regeneron Pharmaceuticals, Inc.): probabilistic price forecasts, technical signals, peer comparison, institutional ownership, earnings history, and social sentiment. Latest AI outlook: Bullish.
← Healthcare Stocks
Last price: $759.05 · Market cap: $80.0B · AI outlook: Bullish
Regeneron Pharmaceuticals, Inc. demonstrates strong growth potential driven by a diversified and innovative portfolio, strategic partnerships, and a history of outperforming earnings expectations, despite facing some regulatory and industry-specific challenges. The 1-year, 5-year, and 10-year projections indicate substantial bullish prospects, supported by the company's ability to secure FDA…
Probabilistic 1-Year Outlook
- Bull 45% · Neutral 35% · Bear 20%
- 1-year price estimates — P10: $500 / P50: $820 / P90: $950
- Regeneron's positive catalysts, including strategic collaborations and FDA approvals, are expected to drive near-term growth. Supply chain challenges and regulatory delays pose some risks. Analysts are optimistic with a…
5-Year Outlook
- Bull 55% · Neutral 30% · Bear 15%
- 5-year price estimates — P10: $300 / P50: $1,200 / P90: $2,400
SWOT Highlights
- Strength: Strong innovative pipeline
- Strength: Collaborations with key players in biotechnology
- Risk: Dependence on specific flagship products
- Risk: Supply chain and regulatory challenges
Major Catalysts
- [object Object]
- [object Object]
- [object Object]
Analyst Coverage & Dividends
24 Wall Street analysts rate REGN a BUY with a mean price target of $819.54. Regeneron Pharmaceuticals, Inc. currently pays a dividend with a yield of approximately 0.50%.
Last analyzed · Model: gpt-4o. How this forecast works · Accuracy & validation.
REGN forecast details · REGN sentiment details
Recent saved forecast research
AI-generated research records, not evaluated investment results.
- Regeneron Pharmaceuticals, Inc. (REGN) — saved
Regeneron Pharmaceuticals, Inc. demonstrates strong growth potential driven by a diversified and innovative portfolio, strategic partnerships, and a history of outperforming earnings expectations, despite facing some regulatory and industry
- Regeneron Pharmaceuticals, Inc. (REGN) — saved
Regeneron Pharmaceuticals, Inc. exhibits strong fundamentals backed by a robust drug pipeline and consistent financial success. While short-term market dynamics, such as legal disputes and competition, pose challenges, the company's ability
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.